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Kinetic characterization of GES-22 β-lactamase
harboring the M169L clinical mutation
Aysegul Saral1,2, David A Leonard3, Azer Ozad Duzgun4, Aysegul Copur Cicek5, Cynthia M June3 and
Cemal Sandalli2
The class A β-lactamase GES-22 has been identified in Acinetobacter baumannii isolates in Turkey, and subsequently shown to
differ from GES-11 by a single substitution (M169L). Because M169 is part of the omega loop, a structure that is known to
have major effects on substrate selectivity in class A β-lactamases, we expressed, purified and kinetically characterized this
novel variant. Our results show that compared with GES-116×His, GES-226×His displays more efficient hydrolysis of penicillins,
and aztreonam, but a loss of efficiency against ceftazidime. In addition, the M169L substitution confers on GES-22 more
efficient hydrolysis of the mechanistic inhibitors clavulanic acid and sulbactam. These effects are highly similar to other
mutations at the homologous position in other class A β-lactamases, suggesting that this methionine has a key structural role
in aligning active site residues and in substrate selectivity across the class.
The Journal of Antibiotics (2016) 69, 858–862; doi:10.1038/ja.2016.48; published online 11 May 2016
INTRODUCTION
β-Lactamases are bacterial enzymes that hydrolyze β-lactam
antibiotics, rendering these compounds ineffective.1 These enzymes
are grouped into four classes A, B, C and D, with class A, C and D
enzymes making use of a catalytic serine to hydrolyze the β-lactam
ring, and class B enzymes using a metal cofactor (Zn). Penicillins and
cephalosporins have been used to treat bacterial infections, but their
efficacy has been greatly diminished by resistance mechanisms.
When these antibiotics began to be inactivated by class A β-lactamases,
several generations of cephalosporins were developed for use in
clinical settings. Inappropriate use of these drugs resulted in the
extended-spectrum β-lactamases (ESBL).2 ESBLs confer resistance to
penicillins, first-, second- and third-generation cephalosporins, and
aztreonam (but not the cephamycins or carbapenems) and they are
inhibited by β-lactamase inhibitors. ESBL type β-lactamases are found
most commonly in class A, though there are a growing number of
examples in class C and D.3 Most class A ESBLs are found in the TEM,
SHV and CTX-M families,1 though variants in PER, VEB, TLA-1,
GES/IBC, SFO-1 and BES-1 have also been reported.4
Acinetobacter baumannii is a Gram-negative, opportunistic pathogen
that causes a range of infections, including bacteraemia, pneumonia,
meningitis, urinary tract infections and wound infections.5 ESBLs
from the Ambler class A group including VEB-1, PER-1, PER-2,
TEM-92, TEM-116, CTXM-2, CTX-M-43, GES-11, -12, -14, -22 and
-24 have been found in A. baumannii.6
The origin of GES-type β-lactamases remains unknown, but
they generally are found in class 1 integron gene cassettes on both
chromosomes and plasmids.7 The first GES β-lactamase, GES-1,
was described in France in 2000.8 This enzyme confers resistance
to penicillins, narrow- and expanded-spectrum cephalosporins
and ceftazidime,9 and 26 variants have been reported to date
(http://lahey.org/studies/other.asp). GES-2 showed better hydrolytic
efficiency against imipenem than GES-1, and its activity was less
inhibited by clavulanic acid, tazobactam and imipenem than GES-1.
There is a single amino acid change between GES-1 and GES-2
(G170N) at position 170 in the omega loop of Ambler class A
enzymes.8 GES-3 has two amino acid substitutions compared with
GES-1 (E104K, M62T).10 Substitution at the G243 residue in GES-9
and GES-11 confers increased activity against aztreonam and
ceftazidime.9 GES-4, -5, -6 and -14 possess a substitution at the
G170 residue (N or S) that leads to carbapenemase activity.11 GES-12
differs from GES-11 by a single amino acid (T237A), which causes
twofold higher efficiency against aztreonam and ceftazidime. GES-14,
with two amino acid substitutions (G243A and G170S), can hydrolyze
both oxyimino-cephalosporins and carbapenems.9
GES-type β-lactamases have been found in Pseudomonas aeruginosa,
Escherichia coli, Klebsiella pneumoniae, Aeromonas media, Aeromonas
veronii, Klebsiella oxytoca, A. baumannii, Serratia marcescens and
Enterobacter cloacae. More recently, GES-22 was found in an
A. baumannii isolate from Turkey.12 GES-22 differs from GES-11 by
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one amino acid substitution M169L, the only known variant at this
position. GES-22 and its parent GES-11 have been reported in
previous studies from Turkey.5,13 In another study from Kuwait,
GES-type ESBLs were found in A. baumannii.14 Altogether, these
studies show that the Middle East and Turkey could be a reservoir for
A. baumannii producing GES-type ESBLs.5 Sequencing of the integron
carrying blaGES-11 and blaGES-22 in isolates from Turkey show that
they possess the same genetic structure as GES-11 from France.
This suggests that GES-22 evolved from GES-11 under conditions of
antibiotic stress with one amino acid change.12
Position 169 is located in the omega loop of class A β-lactamases
including members of the GES-type β-lactamases (Figure 1). In a
previous study of the SHV β-lactamase subfamily, it was shown that
the substitution R169L in SHV-57 induced a conformational change
in N170. This mutation that causes resistance to ceftazidime, but not
to cefazolin is inhibited with clavulanic acid.15 Also, increased
ceftazidime hydrolysis caused by mutations at position 169 have been
described in other studies.16–18 Position 169 is most typically
occupied by methionine or leucine in class A β-lactamases, though
some exceptions exist (TLA-2, SHV-57, CTX-M-93; Figure 2). The
neighboring residue at position 170 is important in imipenem
hydrolysis in GES-type β-lactamases.11,19 The residue at position 170
affects the conformation of the active site of the GES-type β-lactamases
through interactions with the E166 side chain. The presence of a
hydrogen-bonding interaction between S170 and E166 has been
found to be vitally important for carbapenemase activity.19
Given the importance of M169 and other proximal residues, we
wished to determine whether position 169 in GES-22 altered
the activity of this β-lactamase against pencillins, cephalosporins
and carbapenems. Toward this aim, we purified the enzyme and used
steady-state kinetic analysis to measure its activity against a wide
variety of these substrates.
MATERIALS AND METHODS
Plasmids
The genes coding GES-11 and GES-22 in A. baumannii isolates were
amplified by using PCR.5,20 These coding regions were cloned into the
pET28a expression vector using EcoRI and XhoI restriction sites. The signal
peptides of GES-22 and GES-11 were determined using SignalP 4.1 server
(http://www.cbs.dtu.dk/services/SignalP/). The DNA sequences of GES-11 and
GES-22 without the signal sequence (that is, the first 18 residues) were
amplified using iProof High-Fidelity DNA Polymerase (Bio-Rad, Hercules, CA,
USA) and primers with restriction sites for EcoRI and XhoI (GES_EcoRI_F: 5′-
GAATTCTCGGAAAAATTAACCTTCAAGACC-3′ and GES _XhoI_R: 5′-
CTCGAGCTATTTGTCCGTGCTCAGGATGA-3′). After restriction, the PCR
amplicons were introduced into pET28a with T4 DNA ligase. Sequencing of the
coding regions was carried out by Macrogen, Seoul, Korea. Sequencing results
were analyzed using the alignment search tool BLAST (http://www.ncbi.nlm.
nih.gov/BLAST) and the multiple sequence alignment program CLUSTALW
(http:// www.ebi.ac.uk/Tools/msa/clustalw2/).
Expression and purification of GES-22 and GES-11
pET28a-GES-22 and pET28a-GES-11 were transformed into E. coli BL21 (DE3)
for overexpression. E. coli cells harboring pET28a-GES-22 and pET28a-GES-11
vector were grown to an OD at 600 nm of ~ 0.6 in LB medium containing
kanamycin (25 μg ml− 1) at 37 °C, and overexpression was induced by the
addition of 0.1 mM isopropyl β-D-thiogalactopyranoside overnight at 18 °C.
The cells were collected by centrifugation and lysed by sonication.
After sonication, the lysate was centrifuged at 15 000 r.p.m. in a Sorvall
SS-34 rotor (Sorvall, Newtown, CT, USA) for 30 min at 4 °C. The clarified
supernatants were loaded onto a HisPur Cobalt Resin (Thermo Fisher
Scientific, Rockford, IL, USA) equilibrated with 50 mM Tris-HCl, 0.5 M NaCl,
10 mM imidazole, pH 7.4. The column was then washed extensively with
column equilibration buffer, and then washed with 50 mM Tris-HCl, 0.5 M
NaCl, 25 mM imidazole, pH 7.4. The purified β-lactamase protein was eluted
with 50 mM Tris-HCl, 0.5 M NaCl, 250 mM imidazole, pH 7.4. The GES-22 and
GES-11 containing fractions were pooled and dialyzed against 50 mM Tris-HCl,
0.2 M NaCl, pH 7.4 overnight. The protein concentrations were determined by
measuring absorbance at 280 nm, and its purity was shown to be 495% by
SDS-PAGE. Protein samples were stored at − 80 °C.
Determinations of kinetic parameters
The kinetic parameters of the GES-22 and GES-11 were determined with
several β-lactamase substrates by UV spectroscopy (Cary 60, Agilent, Santa
Clara, CA, USA). Hydrolysis of substrates was carried out in 100 mM sodium
phosphate buffer pH 7.0 at room temperature. Initial velocities were obtained
from the change in absorbance per second and converted into velocity units of
μM s using the Beer–Lambert's Law equation, as described previously.21
Changes in absorbance as a function of time were converted to velocity
(μM s− 1) using the following Δε values (M cm− 1): ampicillin, − 900
(λ= 235 nm); penicillin G, − 560 (λ= 240 nm); imipenem, − 9000
(λ= 300 nm); cefotaxime, − 7500 (λ= 260 nm); ceftriaxone, − 9400
(λ= 260 nm); ceftazidime, − 8660 (λ= 260 nm); cefoxitin, − 7700
(λ= 260 nm); aztreonam, − 700 (λ= 320 nm); nitrocefin, +15 000
(λ= 482 nm); clavulanic acid, − 1630 (λ= 235 nm); and sulbactam, +1784
(λ= 236 nm). All experiments were carried out in triplicate. Microsoft Excel
+SDAS (Microsoft Corporation, Redmond, WA, USA) was used to fit the data
to the Michaelis–Menten equation and to determine the Km and kcat values. For
the Km values that were too low or too high to be measured by UV
spectroscopy, Ks values were determined by competition with a nitrocefin
reporter substrate and the Cheng–Prusoff equation.22 For very high Km values,
kcat/Km values were determined directly under the conditions in which [S] oo
Km, and kcat was determined indirectly from kcat/Km and Km.
RESULTS
In order to examine the effects of the M169L substitution, we
expressed and purified both GES-11 M169 and GES-22 M169L.
Constructs for each gene were set up to produce a 6× -histidine tag
followed by mature proteins (that is, with no export sequences)
starting with position 19 (SEKL…). Expression and purification of
GES-11 and GES-22 using a cobalt-affinity column yielded 7–11 mg of

















Figure 1 Overall structure of GES-1. The conserved element 1 (S70-K73) is
in magenta, conserved element number 2 (S130-N132) is in yellow,
conserved element number 3 (K234-G236) is in orange and the omega loop
(residues E166, P167, M169 and G170) is in green. G243, T237, E104
and G170 are important residues in substrate selectivity of GES-type
β-lactamases. (PDB: 3V3R).
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SDS-PAGE. We have not determined the effect of the 6× -histidine tag
on the kinetics, so we limit our analysis to comparisons between the
similarly tagged GES-11 and GES-22.
Purified GES-11 and GES-22 were used to determine the kinetic
parameters for a variety of β-lactam substrates via UV–visible spectro-
scopy (Table 1). The substitution at position 169 in GES-22 led to an
overall increase in the efficiency of hydrolysis for two substrates as
reflected by increases in kcat/Km ratios of 43–240%. Most notably, the
kcat for aztreonam increased from 24 to 120 s
− 1, whereas its Km
increased from 1500 to 3200 μM. Gains in turnover (kcat) between
GES-11 and GES-22 were observed for the two penicillin substrates
tested, penicillin G (3.7–34 s− 1) and ampicillin (21–71 s− 1; Table 1).
As with aztreonam, the gains in kcat for the two penicillins were offset
by higher Km values, thereby moderating the overall gain of efficiency
observed in the presence of the M169L substitution. A different trend
was observed for the oxyiminocephalosporin ceftazidime, for which
the M169L substitution led to a lower kcat (40–17 s
− 1) and no
significant change in Km (1400–1350 μM).
Next, GES-11 and GES-22 were tested for their ability to hydrolyze
the mechanistic inhibitors sulbactam, clavulanic acid and tazobactam.
We observed a 10-fold decrease in Km for clavulanic acid when the
M169L substitution was added to GES-11 to make GES-22 (41–4.8 μM;
Table 2). This apparent increase in binding affinity was offset by a
modest decrease in kcat, but the overall kcat/Km ratio still increased
~ threefold (0.011–0.032 μM− 1 s− 1). The change in kinetic parameters
observed between GES-11 and GES-22 for sulbactam were reflected in
a modest increase in both kcat and Km and an ~ 50% reduction in
kcat/Km. No turnover of tazobactam was observed by either GES-11 or
GES-22, and its binding affinity (KS determined by competition assay)
was unaffected by the mutation.
Representatives of two other substrate classes tested, cefoxitin and
imipenem, showed minor changes in parameters between GES-11
and GES-22, but the activities were so close to the limit of detection
for these substrates that the trends are not deemed reliable.
DISCUSSION
Our analysis of the effect of the M169L substitution on the hydrolytic
activity of GES-type β-lactamases toward a wide variety of β-lactam
substrates reveals interesting trends. The presence of the leucine at this
position leads to an apparent increase in catalytic turnover, but a loss
of affinity, for penicillin G and aztreonam. Conversely, the same
substitution leads to a decrease in the rate of catalytic turnover toward
ceftazidime. Although this pattern may appear somewhat scattered at
first, it is highly notable that very similar trends have been observed
when the homologous positions in other class A β-lactamases
have been substituted. The presence of a leucine at this position in
CTX-M-27 (compared with a glutamine in CTX-M-93) is also
associated with higher activity against aztreonam and several
penicillins, but lower activity against ceftazidime.16 SHV-1, which also
has a leucine at positon 169, displays a similar pattern of activity: lower
activity against ceftazidime, but higher activity against penicillins when
compared with SHV-57 (with an arginine at position 169).15 A C169L
substitution in TLA-2 shows increased activity against penicillins.23
The presence of a leucine in OXY-2-2 lowers ceftazidime resistance
but increases resistance against penicillins and aztreonam compared
with OXY-2-15, which contains a deletion of two residues (168 and
169).24 In another striking similarity, the presence of a leucine in
SHV-1, TLA-2 C169L and OXY-2-2 consistently leads to higher
susceptibility to clavulanic acid compared with their counterparts that
have a substitution or deletion at that position. Our results, along with
these other studies, thus confirm that the identity of the residue at this
key omega loop position displays distinct effects on ceftazidime
compared with other cephalosporins across the class A β-lactamase
Figure 2 Class A β-lactamase sequence alignment. Various class A β-
lactamases were aligned using ClustalW, and the portion of the proteins
surrounding M169 is shown.
Table 1 Kinetic data for GES-116×His and GES-226×His for normal
β-lactam substrates
Km or KS (μM) kcat (s−1) kcat/Km (μM s−1)
GES-116×His
Ampicillin 51±3 21±0.3 0.41±0.02
Penicillin G o15 3.7±0.2 40.25
Ceftazidime 1400±250a 40±7 0.029±0.001
Cefotaxime 2800±500a 340±60 0.12±0.01
Cefoxitin 20±3 0.033±0.002 0.0017±0.0003
Ceftriaxone 1800±300a 260±40 0.14±0.01
Aztreonam 1500±200a 24±4 0.016±0.001
İmipenem 0.13±0.01a 0.0092±0.0004 0.070±0.006
Nitrocefin 170±20 120±5 0.68±0.10
GES-226×His
Ampicillin 121±10 71±2 0.59±0.05
Penicillin G 52±8 34±1 0.65±0.10
Ceftazidime 1350±210a 17±3 0.013±0.001
Cefotaxime 2050±190a 320±30 0.16±0.01
Cefoxitin 19±6 0.014±0.001 0.00072±0.00022
Ceftriaxone 1550±220a 340±50 0.22±0.01
Aztreonam 3200±280a 120±10 0.039±0.001
İmipenem 0.11±0.02a 0.013±0.001 0.11±0.02
Nitrocefin 270±20 320±10 1.2±0.1
aKS values determined by competition kinetics with ampicillin and nitrocefin as the reporter
substrates.
Table 2 Kinetic data for GES-116×His and GES-226×His for inhibitors
KS (μM) Km (μM) kcat (s−1) kcat/Km (μM s−1)
GES-116×His
Tazobactam 1.6±0.3 — — —
Clavulanate 9.3±1.4 41±4 0.42±0.01 0.011±0.0001
Sulbactam 6.1±1.6 23±7 0.33±0.01 0.014±0.004
GES-226×His
Tazobactam 1.2±0.14 — — —
Clavulanate 0.73±0.08 4.8±1.4 0.15±0.01 0.032±0.0095
Sulbactam 10±2 110±61 0.83±0.10 0.0078±0.0045
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family. In addition, common effects can be observed in the modula-
tion of activity toward penicillins, clavulanic acid and sulbactam.
The location of M169 in the structure of GES-11 makes it
unsurprising that substitutions there affect cephalosporin binding
and turnover. M169 is part of the omega loop, which is known to
affect substrate selection in Classes A, C and D β-lactamases.25
Alignment of GES-11 with the class A β-lactamase Toho-1 bound to
cefotaxime shows that the bulky thiazolidine ring of that drug would
be expected to make very close contact with the β-carbon (3.3 Å) and
the carbonyl oxygen (3.0 Å) of P167, a residue that sits on the opposite
side of a short α-helix from M169 (Figure 3).26 In addition, M169 is at
the center of a hydrophobic core, making van der Waals contacts with
the side-chain of F72, M68, the γ-carbon of E166 and the β-carbon of
D176 (Figure 4).27 There are several plausible mechanisms by which
the substitution of a leucine for a methionine at this position might
affect substrate binding and/or catalytic turnover. First, the close
proximity of position 169 to the general base E166 means that a
substitution of the former residue could lead to subtle changes in the
orientation of the carboxylate of the latter, modulating its ability to
activate the deacylating water. If the substitution increased the general
base activity of E166, for instance, it could be responsible the
approximately fivefold increase in kcat observed for the substrate
aztreonam or approximately ninefold increase for penicillin G.
Second, the addition of a γ-branched carbon on leucine might disrupt
the tight packing observed in the hydrophobic core. Alternatively, the
substitution of leucine for methionine shortens the side-chain, and
may lead to similar structural rearrangements. Even small changes in
packing could be transmitted through the α-helix to residues that
would be expected to directly contact the substrate (for example
P167). If such structural rearrangements led to less room for substrate
binding, we might expect the substitution to lead to higher Km values
(for instance, the two to threefold increases we observe for penicillin
substrates and aztreonam).
The structure of GES-1 with imipenem (PDB: 4GOG) bound to it
shows that the hydroxyethyl moiety of the inhibitor makes very close
contacts to the α-carbon (4.3 Å) and main-chain nitrogen (4.7 Å)
of G170.19,28 The carbapenem hydroxethyl moiety has been shown to
influence the activation of water for deacylation of these drugs in more
than one class of β-lactamase,29 so therefore, it is not surprising that
substitutions at the 170 position lead to gains in hydrolytic activity
toward carbapenems.8,9,11 It is interesting that the M169L substitution
at a position so close to G170 leads to an increase in binding and
hydrolysis of many β-lactams, but not carbapenems. This suggests that
the acquisition of gain-of-function activity against carbapenems occurs
by a different mechanism than that observed for the other classes of
substrates.
Figure 3 Superposition of GES-11 (PDB: 3V3R; green) with the class A β-lactamase Toho-1 E166A (PDB 1IYO; cyan) in complex with cefotaxime (magenta).
Residues P167, N170, S237, D240, and R274 create a binding site for the bulky thiazolidine side chain of cefotaxime in Toho-1 E166A structure complex.
Figure 4 The hydrophobic environment around M169. The side-chain of M169 makes contacts with F72, M68, the γ-carbon of E166 and the β-carbon of
D176. This group of side-chains forms a hydrophobic core directly underneath the omega loop.
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Finally, we note the somewhat puzzling observation that gains in
hydrolytic activity for aztreonam appears to have arisen from a gene
present in A. baumannii, for which this drug is not typically used for
treatment. This is a phenomenon, however, that has been observed
in several instances for both class C and class D β-lactamases in
A. baumannii.21,30 One possible explanation is that these drugs are
used for the treatment of patients infected by A. baumannii and a
different species for which these drugs are used (for example,
P. aeruginosa). Another possibility is that A. baumannii infections
arise during the course of prophylactic treatment with these
antibiotics, thus resulting in exposure to them. In either case, it must
be assumed that the A. baumannii strains initially retain some
susceptibility to these drugs but can selectively evolve enzymes that
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